Compare ACIU & FTF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACIU | FTF |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.3M | 249.3M |
| IPO Year | 2016 | N/A |
| Metric | ACIU | FTF |
|---|---|---|
| Price | $3.53 | $6.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 420.0K | 153.9K |
| Earning Date | 03-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.45% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,482,957.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $644.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.43 | $5.76 |
| 52 Week High | $4.00 | $6.56 |
| Indicator | ACIU | FTF |
|---|---|---|
| Relative Strength Index (RSI) | 55.21 | 50.79 |
| Support Level | $3.24 | $6.20 |
| Resistance Level | $3.90 | $6.29 |
| Average True Range (ATR) | 0.26 | 0.04 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 50.00 | 30.00 |
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Franklin Limited Duration Income Trust is a closed-end investment company based in the United States. It conducts its investment to provide high, current income, with a secondary objective of capital appreciation. To align with its investment objective is to invest in a diversified mix of fixed-income securities. Its portfolio is dominated by considerable investments in high-yield corporate bonds while touching upon other avenues such as senior secured floating rate corporate loans, mortgage-backed securities, commercial mortgage-backed securities, asset-backed securities, common stocks, and other short-term investments.